CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer.
收藏NIAID Data Ecosystem2026-05-10 收录
数据链接：
官方服务：
资源简介：
Datasets associated with CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Boumelha, J., de Castro, A., Bah, N., Cha, H., de Carné Trécesson, S., Rana, S., ... & Downward, J. (2024). CRISPR–Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Cancer research, 84(14), 2231-2246.
创建时间：
2026-01-02
